

Special Issue

Pharmacoepidemiology and Addiction—2nd Edition

Message from the Guest Editor

This Special Issue aims to update the current or shifting trends in substance use, the identification of novel psychoactive substances, the development of novel pharmacologic treatments for mono- or polysubstance use, outcome research for currently established pharmacologic treatments of addiction, the integration of pharmacologic treatments for comorbid conditions into addiction medicine and the development of pharmacologic interventions for drug overdose or other adverse outcomes. This issue will accept original research articles, review articles, commentaries, letters or other materials facilitating the understanding of addiction through pharmacoepidemiology.

Guest Editor

Dr. Matthew Ellis

Department of Psychiatry, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA

Deadline for manuscript submissions

closed (31 May 2025)



Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



mdpi.com/si/202378

Pharmacoepidemiology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



About the Journal

Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario
Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 3.2 days (median values for papers published in this journal in the first half of 2025).